PediCAP Trial Finds Early Switch to Oral Antibiotics Safely Cuts Hospital Stays for Severe Pneumonia

PediCAP Trial Results Support Safe Switch to Oral Antibiotics

Severe pneumonia remains a leading cause of childhood mortality and hospitalization across the globe, particularly in resource-limited regions. Under existing World Health Organization guidelines, severe childhood pneumonia typically requires hospital admission and a full five days of injectable antibiotics. In medical practice, this means young patients often stay the entire five days even after experiencing substantial clinical improvement, while milder cases are managed with three to five days of oral medications.

Design and Findings of the International Trial

To determine if stepping down to oral therapy is just as effective as remaining on intravenous treatment, an international team of investigators randomly assigned 1,101 children aged two months to six years with severe community-acquired pneumonia across 13 hospitals in sub-Saharan Africa. Specifically, the research took place in South Africa, Uganda, Zambia, Zimbabwe, and Mozambique, with trial funding provided through the European Union’s EDCTP2 programme and sponsorship by the National Health Executive.

Participants were divided to receive either an oral amoxicillin step-down, an oral amoxicillin-clavulanate step-down, or a continuation of the standard five-day intravenous course. The primary measured outcome was hospital readmission or all-cause death at 28 days, utilizing a non-inferiority margin of 10 percent. The recorded rates for this primary outcome were:

• Amoxicillin step-down group: 5.6 percent (or approximately 6 percent)
• Amoxicillin-clavulanate group: 6.9 percent (or approximately 7 percent)
• Intravenous-only group: 6.3 percent (or approximately 6 percent)

Adverse events remained similar across all three trial arms. Furthermore, children assigned to the oral step-down groups received a median of two days of intravenous antibiotics and stayed in the hospital for a median of 5.5 days, compared to 6.5 days for the intravenous-only group. The data additionally showed that oral antibiotic courses lasting four to five days worked just as effectively as longer courses lasting seven to eight days.

Implications for Healthcare Costs and Antibiotic Stewardship

The trial found no evidence that the broader-spectrum amoxicillin-clavulanate outperformed plain amoxicillin. Study authors emphasized that this distinction is crucial because plain amoxicillin is both cheaper and more widely available, while choosing the narrower drug also reduces selective pressure toward antibiotic resistance.

This simple change could help children get back to their families sooner, reduce pressure on busy hospitals, lower healthcare costs and avoid sometimes catastrophic financial impacts on families from lost caregiver earnings, said first author Julia Bielicki, PhD, MPH, a professor of pediatric infectious disease at City St. George’s, University of London, in a statement accompanying the findings.

Researchers noted that shorter hospital stays minimize patient exposure to the hospital environment itself, which carries inherent risks including contact with resistant organisms. By cutting unnecessary inpatient days, health systems can better optimize limited resources while protecting households from the financial burdens associated with extended stays and lost caregiver wages.